Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Labeling errors & mix-ups

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose.

1,411 FDA drug recalls with this cause, newest first.

This is exactly what it sounds like: the wrong label on the right product, the wrong strength printed on the bottle, a missing or illegible lot number and expiry date, or two products mixed up during packaging. It is dangerous precisely because the pill or liquid itself may be fine, yet the patient has no way of knowing what they are actually taking. A high share of the Class I recalls in this group are mix-ups where a stronger product ended up in a weaker product's packaging.

Class III · Low risk

treatNOW ABILIFY

Labeling Not Elsewhere Classified: Physician sample kits/cartons of treatNOW Abilify are mislabeled. Product name is misspelled, storage instructions are missing and contents of kits may be incorrectly labeled on the outer packaging of the co-packaged kit.

Terminated Labeling / mix-up Otsuka Pharmaceutical Development & Commercialization, Inc. D-0017-2019
Class I · High risk

robaxin-750

Labeling: Incorrect Instructions: Dosage information on the immediate container label incorrectly states "Two to four tablets four times daily." rather than the correct dosage of "Two tablets three times daily."

Terminated Labeling / mix-up Endo Pharmaceuticals, Inc. NDC 52244-449-10 D-0009-2019
Class I · High risk

Hydrochlorothiazide Tablets USP

Product Mix-Up: customer complaint that a sealed bottle labeled as Hydrochlorothiazide Tablets USP 12.5 mg contained only Spironolactone Tablets USP 25 mg.

Terminated Labeling / mix-up Accord Healthcare, Inc. NDC 16729-182-01 D-1206-2018
Class III · Low risk

Oxycodone and Acetaminophen Tablets

Labeling: Incorrect or Missing Lot and/or Exp Date: Lot FG10517 is mislabeled on the primary container with Lot FG01517, shipper labels and invoices contain the correct lot number of FG10517.

Terminated Labeling / mix-up Mayne Pharma Inc NDC 68308-841-01 D-1129-2018
Class I · High risk

Montelukast Sodium Tablets 10 mg

Labeling: Label Mix-Up - One lot labeled Montelukast Sodium Tablets 10 mg tablets may contain 90 tablets of Losartan Potassium 50 mg.

Ongoing Labeling / mix-up Hetero Labs Limited Unit V NDC 31722-726-30 D-0081-2019
Class III · Low risk

Testosterone 200 mg Pellet

Labeling: Incorrect or Missing Lot and/or Exp Date: Incorrect expiration date on label

Terminated Labeling / mix-up Right Value Drug Stores, Inc. D-1047-2018
Class III · Low risk

Diazepam Rectal Gel

Labeling: Incorrect or Missing Lot and/or Exp Date: Product distributed without a lot number or expiration date on the outer carton.

Terminated Labeling / mix-up Valeant Pharmaceuticals North America LLC NDC 68682-650-20 D-1041-2018
Class I · High risk

Neostigmine Methylsulfate Injection Solution

Labeling: Label Error on Declared Strength: syringes of Neostigmine Methylsulfate 1 mg per mL, 5 mg per 5 mL may be incorrectly labeled as Neostigmine Methylsulfate 1 mg per mL, 3 mg per 3 mL.

Terminated Labeling / mix-up Fagron Compounding Services LLC dba Fagron Sterile Services NDC 71266-2003-01 D-0911-2018
Class I · High risk

Neostigmine Methylsulfate Injection Solution

Labeling: Label Error on Declared Strength: syringes of Neostigmine Methylsulfate 1 mg per mL, 5 mg per 5 mL may be incorrectly labeled as Neostigmine Methylsulfate 1 mg per mL, 3 mg per 3 mL.

Terminated Labeling / mix-up Fagron Compounding Services LLC dba Fagron Sterile Services NDC 71266-2003-02 D-0910-2018
Class III · Low risk

Equate ClearLAX

Labeling: Not Elsewhere Classified - A private label distributor noted unfiled NDC numbers on EQ ClearLax Polyethylene Glycol 3350 NF Powder Solution of various sizes.

Terminated Labeling / mix-up Lupin Somerset NDC 49035-312-07 D-0907-2018
Class III · Low risk

Riomet (metformin hydrochloride oral solution)

Labeling: Not Elsewhere Classified: Sun Pharma has decided to initiate this recall in response to identified labeling discrepancies in the patient literature.

Terminated Labeling / mix-up Sun Pharmaceutical Industries, Inc. NDC 10631-206-02 D-0818-2018
Class II · Moderate risk

Acetaminophen 300 mg with Codeine Phosphate 30 mg tablets

Labeling: Not Elsewhere Classified: due to a labeled declaration of; Store at 15¿C to 30¿C (59¿F to 86¿F) which differs from the original manufacturer declaration of; Store at 20¿C to 25¿C (68¿F to 77¿F).

Terminated Labeling / mix-up Prescript Pharmaceuticals, Inc. D-0809-2018
Class II · Moderate risk

Clindamycin 300 mg capsules

Labeling: Not Elsewhere Classified: due to a labeled declaration of; Store at 15¿C to 30¿C (59¿F to 86¿F) which differs from the original manufacturer declaration of; Store at 20¿C to 25¿C (68¿F to 77¿F).

Terminated Labeling / mix-up Prescript Pharmaceuticals, Inc. D-0808-2018
Class II · Moderate risk

Chlorhexidine 0.12% liquid

Labeling: Not Elsewhere Classified: due to a labeled declaration of; Store at 15¿C to 30¿C (59¿F to 86¿F) which differs from the original manufacturer declaration of; Store at 20¿C to 25¿C (68¿F to 77¿F).

Terminated Labeling / mix-up Prescript Pharmaceuticals, Inc. D-0807-2018
Class II · Moderate risk

Acetaminophen 300 mg with Codeine Phosphate 30 mg tablets

Labeling: Not Elsewhere Classified: due to a labeled declaration of; Store at 15¿C to 30¿C (59¿F to 86¿F) which differs from the original manufacturer declaration of; Store at 20¿C to 25¿C (68¿F to 77¿F).

Terminated Labeling / mix-up Prescript Pharmaceuticals, Inc. D-0806-2018
Class II · Moderate risk

Clindamycin 150 mg capsules

Labeling: Not Elsewhere Classified: due to a labeled declaration of; Store at 15¿C to 30¿C (59¿F to 86¿F) which differs from the original manufacturer declaration of; Store at 20¿C to 25¿C (68¿F to 77¿F).

Terminated Labeling / mix-up Prescript Pharmaceuticals, Inc. D-0805-2018
Class III · Low risk

Calendula Cream

Labeling: Labeling Error on Declared Strength; The outer carton (secondary packaging) statement of ingredients misstates the concentration of active ingredient at 7%. The primary packaging (tube) correctly states the active ingredient at 10%.

Terminated Labeling / mix-up Boiron Inc. D-0803-2018